In this Motley Fool Live segment from "Ask Us Anything," recorded on June 22, Fool.com contributors John Bromels and Brian Withers take a closer look at biotech company Amgen (AMGN +1.69%).
John Bromels: Top-line growth has been basically a single digit percentages, but steady. The company is in fact profitable and so I'm just going to say yes.
Brian Withers: Yeah. I would say, yes.
John Bromels: Brian, this one has just over three percent dividend yield right now, which is pretty decent. But big Biotech seems to be growing. I would say that if I were interested in a dividend payer to provide some balance to my portfolio based on what I have seen so far. Yeah, I would say that this would be one I would probably look further into. It seems like it is executing pretty well and pretty consistently. I know you came in mid discussion, but is that your sense?
Brian Withers: Yeah, and that would be enough for me to go past [laughs].
John Bromels: Really?
Brian Withers: Yeah. Is just out of my circle of confidence, when we got to the pharmaceuticals thing, I'd be like, oh, it's not a software e-commerce company.
John Bromels: But that would be for you, of course. If you were interested in a large biotech.
Brian Withers: Biotech this was proper loan at three percent interest rate, oh yeah. I think that's absolutely a balanced portfolio pick.
